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Conclusions: The results demonstrate that, despite the generally
naïve CB lymphocytes, influenza HA-specific responses can be gen-
erated ex vivo and could be potentially be used to enhance immune
reconstitution following allogeneic stem cell transplantation.
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Background: The purpose of the study was to obtain a quality
graft, which contained the minimum of 2.5x106/kg body stem cells
CD34 viable and functional.
Objectives: The principle was to base the separation of blood cells
using the difference between density gradients. We compared the
harvests on patients with: Hodgkin disease, multiple myloma, neu-
roblastoma, Ewing sarcoma, malignant non-Hodgkins lymphoma,
and acute leukemia.
Material and Methods: The study was undertaken between 2000
till November 2007 on 116 patients (97 patients and 19 donators)
in the Medullar Graft and Transfusions Centre, collaborating with
another department from Fundeni Clinical Institute. The total num-
bers of procedures was 188 (159 patients and 29 donators). The
harvest of peripheral blood stem cells were made by: medullar
aspiring puncture, citaferesys procedure, and/or umbilical vein
puncture, after expelling the afterbirth from uterus. We used de-
vices such as: Haemonetics MCS Plus and Cobe Spectra, and for
harvests made for liver and pancreatic transplantation the Clini-
macs Plus device system.
Results: In the case of harvests for patients with hematological
problems, we obtained 42 grafts CD34 <5x106/KgC and 74 grafts
CD34>5x106/KgC. For patients with diabetes, we obtained 2 grafts
CD34 >5x106/KgC. For patients with liver problems we obtained 4
grafts CD34 <5x106/KgC. All the grafts were bacteriological tested
by harvesting hem-cultures in BACTEC system, results were nega-
tive to the unfreeze blood stem cells graft and also when we veri-
fied the grafts after defrosting.
Conclusions: LVL versus SVL procedures comparison: a) LVL pro-
cedure allow the harvest of a large number of cells CD34+; b)
Viability of the cells CD34+ is not mutated; c) Number of neces-
sary aphaeresis to obtaining minimum 2.5x106 CD34/kgC is smaller
with LVL protocol, comparing with Haemonetics MCS Plus system.
The growing agent mobilization, for patients with liver and pan-
creatic problems, the harvest of CD34+ begins in the z+5-th day. If
you obtain an inadequate graft, you must undertake another blood
stem cells procedure harvest. In the wake of selection made with
Clinimacs Plus system we obtained 2 grafts, containing 0.01x109
leucocytes/bag and 0.001x106 CD34 cells/kgC, respective 1.02x109
leucocytes/bag and 2,18x106/kgC CD34 cells.
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Background: Linezolid has been associated with low rates of re-
versible hematologic toxicities in clinical trials. Linezolid is the
preferred treatment for vancomycin resistant Enterococcus fae-
cium, a frequent cause of bacteremia post HSCT. We assessed the
impact of peri-HSCT Linezolid administration on the time to neu-
trophil and platelet engraftment.
Methods: Retrospective case control study. Cases were HSCT recip-
ients who received at least 7 consecutive days of linezolid starting
by day +7 post HSCT. Controls were matched to cases by age and
type of conditioning regimen and received at least 7 days of van-
comycin starting by day + post HSTC. The initial antibiotic regi-
men for fever and neutropenia was piperacillin/tazobactam plus
amikacin for adults, cefepime plus amikacin for children. Van-
comycin was initiated at the discretion of the treating physician.
Time to neutrophil engraftment (ANC_500) was calculated as the
number of days from stem cell infusion to absolute neutrophil
count (ANC)>500/mL on three consecutive measurements. Time to
platelet engraftment (PLT_20) was defined as the number of days
from stem cell infusion to date of maintaining platelet count (PLT)
>20,000/mL for 3 consecutive measurements without any platelet
transfusion for at least 7 days from the date of last PLT transfu-
sion. Statistical analysis was done using Fisher' s exact test and the
Wilcoxon rank sum test.
Results: Thirty-five cases were compared to 35 controls. Demo-
graphics and transplant characteristics were similar between cases
and controls. The median duration of treatment was 13 days for
linezolid (range 5-28) and 18 days for vancomycin (6-43). The cu-
mulative percentage of patients achieving ANC_500 and PLT_20
at each time point examined was similar for the two treatments
groups. The p-values from the competing risk analysis were not
significant (P=NS). The competing regression model confirmed this
conclusion after adjustment for factors know to affect engraft-
ment. WBC, ANC and PLT counts at 30 days after discontinuing
treatment were similar between the two groups.
Conclusions: Early linezolid administration did not have a negative
impact on time to neutrophil or platelet engraftment post HSCT.
Compared to controls cases had similar values of WBD, ANC and
PLT 30 days after discontinuing treatment. A larger study is needed
to validate our findings and assess the hematologic safety profile
of linezolid in the period of greatest marrow vulnerability.
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Introduction: Human herpesvirus 6 (HHV-6) reactivation may have
significant consequences in cord blood transplant recipients (CBR).
This study evaluates the incidence of HHV-6 reactivation, its man-
ifestations and treatment in CBR at our center.
S18 Infections in Patients with Stem Cell Transplants
Materials and Methods: From 8/2005 to 12/2007, 15 patients (pts),
25-61 years old, with high risk acute leukemias, underwent double
cord blood transplantation. HHV-6 reactivation was noticed in 7
(47%) at a median time of 40 days (range 25-127) post-transplant.
Myeloablative conditioning regimen was used in 5/7. Prophylac-
tic antiviral therapy consisted of acyclovir (n=5/7) or foscarnet
(n=2/7). Among them 2 pts had already CMV-infection and 6 (85.7%)
suffered from aGVHD and received methylprednisolone at the time
of HHV-6 reactivation. Levels of HHV-6 DNA in PBMCs and plasma
by RT-PCR were monitored every week. The viral load in PBMCs
ranged from 0.02 to 5.1 x 104 copies/ml (median 0.41 x 104).
Results: Clinical manifestations included fever, skin rash, throm-
botic microangiopathy, seizures, bone and joint pain, hemophago-
cytosis, persistent thrombocytopenia, and several concurrent in-
fections [bacterial (n=2): Pseudomonas putida, Staphylococcus
epidermidis, Rhizobium radiobacter/fungal (n=2): Aspergillus,
Acremonium/viral (n=4): CMV, EBV, BKV, RSV, Rhinovirus, Boca
virus/parasitic (n=1): toxoplasma gondii. Despite the fact that
the above manifestations could not always be attributed to HHV-
6, it seemed that their emergence and/or aggravation corre-
lated with its reactivation. Engraftment with ANC>microliter and
PLTs>50,000/microliter occurred at median time of 19 (range 6-
34) and 36 (range 41-95) days respectively. Two pts died before en-
graftment. Five pts received foscarnet and all but one responded
at a median time of 10 days (range 9-19). The non-responder re-
ceived cidofovir without response. In 3 pts, despite the reduction
of viral load, viral DNA had been detected for several weeks. With
a median follow up of 5 months (range 3-30), 3 pts died (systemic
toxoplasmosis at d+52, leucoencephalopathy and sepsis at d+93,
disease relapse at d+180).
Conclusions: A high incidence of HHV-6 reactivation with a variety
of manifestations was noticed, that may increase immunosuppres-
sion and predispose to infections, but no clear conclusion could
be made about its impact on engraftment. Further investigation is
needed to identify risk factors for HHV-6 reactivation, and optimal
prophylactic therapy.
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Introduction: Human bocavirus (HBoV) is a recently discovered
parvovirus frequently detected in respiratory samples from chil-
dren during winter. Its role in immunocompromised patients re-
mains unclear. We report a case of HBoV infection in a transplant
recipient.
Materials, Methods and Results: A 33-year-old woman with acute
lymphoblastic leukemia received an allogeneic hematopoietic stem
cell transplant in March 2007, from an unrelated, 9/10 HLA al-
leles matched, donor. On day+306, while in ongoing remission,
she presented with low grade fever, nasal congestion, neutrope-
nia and thrombocytopenia. During this period she had been receiv-
ing tacrolimus, mycophenolate mofetil and methylprednisolone for
persistent chronic GVHD. Anti-infective prophylaxis consisted of
penicillin, posaconazole, acyclovir, atovaquone. Nasopharyngeal
aspirates (NPA) were screened for 17 respiratory viruses (influenza
A, B, C, parainfluenza 1, 2, 3, 4a, 4b, RSV A, B, rinovirus, aden-
ovirus, echovirus, bocavirus, coronovirus, metapneumonovirus A,
B) with PCR/DNA microarrays on day+306. HBoV was the only pos-
itive virus. Concomitantly, CMV reactivation by PCR was identified
from blood. She was started on ganciclovir and one week later PCR
for CMV was negative. The neutrophil count normalized within 10
days but thrombocytopenia and rhinitis persisted and the patient' s
general health was not improved. On d+ 339 her temperature rose
to 39°C, dry cough and diarrhea ensued. d+ Chest radiograph and
CT showed mild pericardial effusion. The bronchoalveoral lavage
fluid was positive for HBoV without isolation of other pathogen.
NPA remained HBoV positive. Intestinal tissue biopsy was not di-
agnostic, but PCR analysis of the intestinal tissue was positive for
HBoV. On d+ 356 dyspnea and hypoxia were added. Chest radio-
graph showed diffuse infiltrations on both lungs. She died despite
respiratory support.
Conclusion: HBoV caused a persistent, disseminated and finally
fatal infection in that immunocompromised patient. Chronic GVHD
and immunosuppressive therapy probably predisposed to viral dis-
semination. Further investigation is required for estimation of
HBoV epidemiology and clinical manifestations in immunocompro-
mised patients.
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Background: Blood stream infections (BSI) remain an important
complication of HSCT. The aim of this study was to analyze etiol-
ogy, microbiological resistance and outcome of BSI after allogeneic
HSCT.
Materials: Retrospective review of BSI in patients treated at HSCT
Unit between 1/01/04 and 31/12/07.
Methods: BSI was defined as isolation of a pathogen from at least
one blood culture. For common skin contaminants, 2 consecutive
positive blood cultures were required. Survival after BSI was ana-
lyzed by univariate chi-square test.
Results: There were 169 episodes of BSI diagnosed in 132 patients
(median 10 days after HSCT, range: -47; 4876) and 183 pathogens
were isolated (Table 1).
Table 1. Etiology of 169 blood stream infections occurring between
01/01/04 and 31/12/07 in allogeneic stem cell transplant recipients
Organism Number (%)
Gram-positive 103 (56%)
Staphylococcus 45
Coagulase negative 41
Staphylococcus aureus 4
Enterococcus 40
Enterococcus faecalis 21
Enterococcus faecium 17
Others (E. avium, E. species) 2
Viridans streptococci 11
Corynebacterium 5
Others (Streptococcus pneumoniae, Rothia mucillaginosa) 2
Gram-negative 69 (38%)
Escherichia coli 25
Pseudomonas aeruginosa 20
Klebsiella pneumoniae 7
Enterobacter 7
Stenotrophomonas maltophilia 4
Burkholderia cepacia 3
Others (2 Pseudomonas species, 1 Acinetobacter species) 3
Candida 11 (6%)
krusei 4
albicans 2
parapsilosis 2
species 2
glabrata 1
